Cologne and Hamburg, Germany, November 5, 2012 / B3C Newswire / - CEVEC Pharmaceuticals (“CEVEC”), the developer of a novel human expression system derived from amniocytes, and CCS Cell Culture Service GmbH (“CCS”), a contract research organization based in Hamburg, Germany, announced today the signing of a strategic license agreement. The license will enable CCS to offer its customers transiently transfected CAP-TTM cells for cell based assay and protein production applications.
The transient CAP-TTM protein production technology is based on CAP® cells, an immortalized cell line for stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.
The collaboration combines CEVEC’s proprietary CAP-TTM expression system with CCS’ expertise to produce and process bulk quantities of transiently transfected cells for drug discovery research in pharmaceutical companies worldwide. “CCS Cell Culture Services is a very experienced and trusted partner for the custom supply of cell based assay reagents. We’re very pleased that they will add our CAP-T cells to their cell based assay technology portfolio and we’re convinced that the cells will contribute significantly to the drug discovery process in the pharma industry " stated Wolfgang Kintzel, CEO at CEVEC.
Oliver Wehmeier, Managing Director of Cell Culture Services said: “We are excited about the potential of CEVEC’s CAP-T technology. The cells meet all requirements for a host cell line in terms of robustness, transfection efficacy, expression level, and scalability. We obtained outstanding results from transient transfections of various secreted, intracellular, or membrane bound target proteins in CAP-T cells and we are pretty sure that this expression system will be of great benefit to our customers”
About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC’s novel proprietary and patent-protected human CAP® and CAP-TTM expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.
About Cell Culture Service GmbH
For more than thirteen years, CCS has been supporting research departments of pharmaceutical and biotechnology companies with custom made functionally validated cell based reagents. CCS is one of the leading suppliers of recombinant cell lines, assay-ready frozen cells, qualified membranes, and proteins for high-throughput screening. Major pharmaceutical companies all over Europe and the USA rely on the custom products and services of CCS.
Contacts:
Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 - 01
info@cevec.com
Dr. Oliver Wehmeier
Managing Director
CCS Cell Culture Service GmbH
Falkenried 88
20251 Hamburg, Germany
fon +49 (0)40 47196560
fax: +49 (0)40 471 965 66
info@CellCultureService.com
